FDA Neuro Devices Panel Examines Suicide Risk In Depression Trial Subjects
This article was originally published in The Gray Sheet
Executive Summary
Clinical trials of devices for depression do not readily lend themselves to hard-and-fast rules on when the rate of patient suicides might require a trial to be halted, according to FDA’s neurological devices panel.
You may also be interested in...
FDA Panel To Look At Controversial Electroshock Device Classification
FDA's neurological devices advisory panel will meet in January to discuss the possible reclassification of devices used in electroconvulsive therapy.
FDA Panel To Look At Controversial Electroshock Device Classification
FDA's neurological devices advisory panel will meet in January to discuss the possible reclassification of devices used in electroconvulsive therapy.
Neuronetics' NeuroStar Depression Therapy Not Backed By Data - Blues
Existing evidence does not support the long-term efficacy of Neuronetics' NeuroStar transcranial magnetic stimulation therapy for drug-resistant depression, according to a recent 1assessment by the Blue Cross and Blue Shield Association Technology Evaluation Center